TBPH News and Press, Theravance Biopharma Inc.

Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders? PR Newswire Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. ...

2026-07-01 08:30:50 ET Thesis - Acquisition of Theravance Biopharma makes upside case As you know, the big news from Zymeworks Inc. ( ZYME ) this week was the acquisition of Theravance Biopharma ( TBPH ) for about $929 million or $17/share. The way I see it, this is ...

2026-06-29 14:36:42 ET More on Theravance Biopharma Theravance Biopharma: A Special Situation With A 50-100% Likely Upside Zymeworks to pay $17/share for Theravance Biopharma in $929M deal Summers Value Fund adds TBPH, exits ADMA among Q1 moves Seeking Alpha&...

Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? PR Newswire Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. ...

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options a...

2026-06-29 06:30:50 ET Read the full article on Seeking Alpha For further details see: Zymeworks to pay $17/share for Theravance Biopharma in $929M deal

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT PR Newswire Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 millio...

2026-05-07 08:42:36 ET More on Theravance Biopharma Theravance Biopharma: A Special Situation With A 50-100% Likely Upside Summers Value Fund adds TBPH, exits ADMA among Q1 moves Theravance drops rare disease drug after late-stage trial setback Seeking Alpha&...

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire YUPELRI ® Collaboration Revenue increased 15% year-over-year 1 , from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved o...

2026-04-29 11:26:39 ET More on Theravance Biopharma Theravance Biopharma: A Special Situation With A 50-100% Likely Upside Theravance drops rare disease drug after late-stage trial setback Seeking Alpha’s Quant Rating on Theravance Biopharma Historical...